Table 1:
Baseline and treatment characteristics
| Variables | No Residual Tumor (NRT) N=135 | Residual Tumor (RT) N=128 | p-value |
|---|---|---|---|
|
| |||
| Age (IQR) | 59 (18) | 57 (17) | 0.32 |
| Female gender | 50 (37) | 38 (29.7) | 0.24 |
| Race/Ethnicity | >0.999 | ||
| White | 109 (80.7) | 104 (81.2) | |
| Non-White | 22 (16.3) | 21 (16.4) | |
| Unknown | 4 (3) | 3(2.4) | |
| cT classification | 0.674 | ||
| cT1 or 2 | 17 (12.6) | 12 (9.4) | |
| cT3 | 102 (75.6) | 99 (77.3) | |
| cT4 | 16 (11.8) | 17 (13.3) | |
| cN positive | 86 (63.7) | 102 (79.7) | 0.004 |
| Tumor distance from AV (IQR), cm | 4 (3.8) | 4.5 (2.9) | 0.775 |
| Treatment arm | 0.014 | ||
| INCT-CRT | 55 (40.7) | 72 (56.2) | |
| CRT-CNCT | 80 (59.3) | 56 (43.8) | |
| Received ≥75% of intended neoadjuvant chemotherapy dose | 115 (85.2) | 107 (83.6) | 0.737 |
| Median radiation dose, cGy (IQR) | 5400 (580) | 5400 (525) | 0.158 |
| Received concurrent chemotherapy with radiation | 134 (99.3) | 128 (100) | >0.999 |
| Median interval TNT to restaging (IQR), weeks | 7.8 (3.3) | 7.7 (3.8) | 0.81 |
Data are reported as n(%) unless otherwise specified. P-values calculated using Fisher’s exact test for categorical variables and Wilcoxon rank sum for continuous variables. Bolded numbers are statistically significant. Abbreviations: cT classification= clinical tumor classification, cN positive= clinical node status positive, AV= anal verge, INCT-CRT = induction chemotherapy followed by chemoradiation, CRT-CNCT= chemoradiation followed by consolidation chemotherapy